- Home
- PMCB vs ENSC Comparison
PMCB vs ENSC Comparison
Compare PMCB & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- ENSC
- Stock Information
- Founded
- PMCB 1996
- ENSC 2003
- Country
- PMCB United States
- ENSC United States
- Employees
- PMCB N/A
- ENSC N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- ENSC Health Care
- Exchange
- PMCB Nasdaq
- ENSC Nasdaq
- Market Cap
- PMCB 6.6M
- ENSC 6.4M
- IPO Year
- PMCB N/A
- ENSC N/A
- Fundamental
- Price
- PMCB $0.93
- ENSC $2.10
- Analyst Decision
- PMCB
- ENSC
- Analyst Count
- PMCB 0
- ENSC 0
- Target Price
- PMCB N/A
- ENSC N/A
- AVG Volume (30 Days)
- PMCB 106.5K
- ENSC 54.6K
- Earning Date
- PMCB 09-15-2025
- ENSC 11-11-2025
- Dividend Yield
- PMCB N/A
- ENSC N/A
- EPS Growth
- PMCB N/A
- ENSC N/A
- EPS
- PMCB 0.01
- ENSC N/A
- Revenue
- PMCB N/A
- ENSC $7,413,722.00
- Revenue This Year
- PMCB N/A
- ENSC N/A
- Revenue Next Year
- PMCB N/A
- ENSC $1,354.55
- P/E Ratio
- PMCB $160.47
- ENSC N/A
- Revenue Growth
- PMCB N/A
- ENSC 415.58
- 52 Week Low
- PMCB $0.80
- ENSC $1.62
- 52 Week High
- PMCB $2.42
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- PMCB 44.27
- ENSC 48.61
- Support Level
- PMCB $1.00
- ENSC $2.02
- Resistance Level
- PMCB $1.08
- ENSC $2.19
- Average True Range (ATR)
- PMCB 0.08
- ENSC 0.10
- MACD
- PMCB -0.00
- ENSC 0.00
- Stochastic Oscillator
- PMCB 2.95
- ENSC 41.45
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.